Cytokinetics Financial Report from Smith On Stocks

Monday, March 1, 2021 · 7:07 am

Wednesday, January 20, 2021 · 9:04 am

Tuesday, January 19, 2021 · 3:49 pm

Tuesday, November 17, 2020 · 8:53 am

Friday, November 6, 2020 · 8:47 am

Thursday, October 8, 2020 · 1:59 pm

Monday, October 5, 2020 · 9:43 am

Thursday, June 11, 2020 · 3:09 pm

Monday, August 19, 2019 · 9:32 am

Tuesday, May 7, 2019 · 12:18 pm

Thursday, March 7, 2019 · 3:05 pm

Thursday, August 2, 2018 · 11:38 am

Thursday, May 17, 2018 · 9:11 am

Tuesday, November 21, 2017 · 8:27 am

Monday, October 30, 2017 · 9:24 am

Monday, August 7, 2017 · 12:48 pm

Monday, May 8, 2017 · 9:48 am

Thursday, April 6, 2017 · 11:32 am

Wednesday, March 15, 2017 · 10:42 am

Wednesday, March 15, 2017 · 10:10 am

Wednesday, March 15, 2017 · 9:36 am

Thursday, February 2, 2017 · 1:50 pm

Thursday, December 1, 2016 · 8:52 am

Friday, November 4, 2016 · 9:25 am

Thursday, September 1, 2016 · 9:47 am

Wednesday, August 17, 2016 · 11:27 am

Wednesday, July 27, 2016 · 12:13 pm

Thursday, June 30, 2016 · 9:38 am

Wednesday, March 23, 2016 · 4:31 pm

Wednesday, March 9, 2016 · 8:52 am

Wednesday, February 10, 2016 · 10:41 am

Monday, December 7, 2015 · 8:31 am

Monday, November 9, 2015 · 10:43 am

Tuesday, October 27, 2015 · 9:51 am

Friday, July 31, 2015 · 12:57 pm

Thursday, July 23, 2015 · 4:25 pm

Sunday, July 5, 2015 · 9:10 am

Tuesday, May 19, 2015 · 9:50 am

Tuesday, May 5, 2015 · 1:07 pm

Tuesday, March 10, 2015 · 10:22 am

Friday, February 20, 2015 · 9:18 am

Wednesday, December 24, 2014 · 8:29 am

Saturday, November 1, 2014 · 9:14 am

Wednesday, August 6, 2014 · 10:20 am

Monday, June 16, 2014 · 2:30 pm

Tuesday, February 18, 2014 · 10:30 am

Friday, February 14, 2014 · 4:28 pm

Wednesday, January 22, 2014 · 3:48 pm

Tuesday, September 24, 2013 · 3:23 pm

Wednesday, September 4, 2013 · 12:51 pm

Thursday, August 8, 2013 · 7:53 am

Monday, March 25, 2013 · 10:11 am

There are 52 reports on file.

Reports on Cytokinetics

Recent Reports

Cytokinetics: Catalysts for 2021 (CYTK, $18.79)

Cytokinetics: Approval of Merck�s Heart Failure Drug Vericiguat Increases My Confidence for Approval of Omecamtiv

Cytokinetics: A Deep Dive into the Potential for Omecamtiv (CYTK, Buy, $19.86)

Cytokinetics: Is Omecamtiv Mecarbil Approvable? Yes! (CYTK, Buy, $15.59)

Cytokinetics: There Still May Be Hope for Omecamtiv Mecarbil (CYTK, Buy, $16.54)

Cytokinetics: Top Line Results for Omecamtiv in GALACTIC-HF Trial Are Perplexing (CYTK, $15.46)

Cytokinetics: Proposed Acquisition Price for MyoKardia Suggests CYTK is Dramatically Undervalued (CYTK, Buy, $27.33)

Cytokinetics (CYTK, Buy, $20.97) Omecamtiv Nears the Finish Line; Topline Data Expected in 4Q, 2020 with Launch Possible in 2021

Cytokinetics: Current Investment Thesis Is All About Omecamtiv Mecarbil (CYTK. $13.26, Buy)

Cytokinetics: Based on Data from Fortitude ALS Trial, Cytokinetics and Astellas Indicate They Will Undertake Phase 3 Trial of Reldesemtiv in ALS (CYTK, Buy, $9.30)

Cytokinetics: A Focus on 2019 Stock Price Catalysts (CYTK, Buy, $5.82)

Cytokinetics: Update based on 2Q, 2018 Conference Call (CYTK, Buy, $6.85)

Cytokinetics: Update on Extensive Clinical Trials Being Conducted (CYTK, Buy, $9.45)

Cytokinetics: VITALITY-ALS Trial Fails (CYTK, Buy, $8.00)

Cytokinetics: Even if Tirasemtiv Were to Fail in Vitality-ALS. There is Great Long term Stock Potential (CYTK, $14.25, Buy)

Cytokinetics: Reiteration of My Long Standing Buy Recommendation Based on an Extraordinary Pipeline (CYTK, $12.90, Buy)

Cytokinetics: What Are the Implications for Tirasemtiv Following the Approval of Radicava (Edaravone) for ALS? (CYTK, Buy, $15.40)

Cytokinetics: Insights into Corporate Collaborations, Tirasemtiv, CK-107 and Hospitalization Caused by Heart Failure (CYTK, Buy, $11.25)

Cytokinetics: A Look at the Clinical Trial Programs Underway (CYTK, Buy, $13.00)

Cytokinetics: Estimating a Potential 2025 Price Target of $220 Based Only on the Potential for Tirasemtiv (CYTK, Buy, $13.00) and Ignoring Omecamtiv Mecarbil and CK-107

Cytokinetics: Estimating a Potential 2025 Price Target of $172 Based Only on the Potential for Omecamtiv Mecarbil and Ignoring Tirasemtiv and CK-107 (CYTK, Buy, $13.00)

Cytokinetics: Discussion of Financing Deal with Royalty Partners (CYTK, Buy, $11)

Cytokinetics: Results of COSMIC HF Published in The Lancet; Phase 3 GALACTIC HF Trial Has Started (CYTK, Buy, $12.00)

Cytokinetics: My Relative Market Value Analysis Suggests that the Stock Should be Selling at More Than $20 (CYTK, Buy, $8.95)

Cytokinetics; Amgen and Servier Announce Decision to Move Omecamtiv Mecarbil into Phase 3 (CYTK, Buy, $12.07)

Cytokinetics: Tirasemtiv Completes Phase 3 Enrollment (CYTK, Buy, $11.89)

Cytokinetics: Collaboration with Astellas is Expanded and Will Bring in $65 Million of Cash (CYTK, $10.45, Buy)

Cytokinetics: Phase 2 Trial of CK-2127107 in COPD Begins (CYTK, $9.37, Buy)

Cytokinetics: Amgen�s R&D Chief Expresses Great Optimism About Omecamtiv Mecarbil for Treating Congestive Heart Failure (CYTK, Buy, $6.53)

Cytokinetics: Comments on the Patent Situation of Omecamtiv Mecarbil (CYTK, Buy, $6.40)

Cytokinetics: An Update Based on CEO Robert Blum�s Comments at BIO CEO Conference on February 8, 2016 (CYTK, Buy, $6.57)

Cytokinetics: An Update on Potential (Highly Probable) Phase 3 Trial of Omecamtiv Mecarbil in Heart Failure (CYTK, Buy, $11.29)

Cytokinetics: I Predict Amgen Will Proceed to Phase 3 Trials with Omecamtiv Mecarbil (CYTK, Buy, $10.82)

Cytokinetics: Positive Topline Results of Omecamtiv in COSMIC-HF Trial Are a Major Positive (CYTK, Buy, $7.04)

Cytokinetics: Comments on Sharp Price Decline After 2Q, 2015 Conference Call (CYTK, Buy, $6.28)

Cytokinetics: Phase 3 Trial of Tirasemtiv Has Begun (CYTK, Buy, $7.17)

Cytokinetics: Phase 3 Trial for Tirasemtiv About to Begin with Topline Results Possible in 2H, 2016; Successful Outcome Could Make the Stock a Homerun (CYTK, $6.35, Buy, For Paid Subscribers)

Cytokinetics: Takeaways from Recent R&D Day and Reiteration of Buy (CYTK, $6.14, Buy)

Cytokinetics: Update and Reiteration of My Buy Recommendation (CYTK, $5.54, Buy)

Cytokinetics: Updates on Tirasemtiv and Omecamtiv (CYTK, Buy, $7.77)

Cytokinetics: Key Catalysts for 2015 Strongly Support My Buy Recommendation (CYTK, $7.85)

Cytokinetics (CYTK, Buy $5.52) New Collaboration with Astellas on CK-2127107 Greatly Improves Investment Outlook

Cytokinetics: An Update on Tirasemtiv and Omecamtiv Mecarbil (CYTK, Buy, $3.67)

Cytokinetics: More Thoughts on the Potential for a Phase 3 Trial of Tirasemtiv in ALS (CYTK, Buy, $4.20)

Cytokinetics: I Think That the Company May Decide to Do A Phase 3 Trial with Tirasemtiv (CYTK, $4.70, Buy, For Subscribers Only)

Cytokinetics: An In-Depth Look at the Potential for Success of Tirasemtiv in the BENEFIT-ALS Trial in ALS Patients (CYTK, $9.50) (Subscribers Only)

The BIO CEO Conference: Highlights from the Meeting and New Investment Perspectives (Subscribers Only)

San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)

Cytokinetics: Presentation at Heart Failure Society Suggests Myocardial Infarctions Are Not Likely Associated with Omecamtiv Mecarbil (CYTK, $7.61)

Cytokinetics: Clinical Investigators� Take on ATOMIC-AHF Trial Results (CYTK, $8.01)

Cytokinetics: A Preview of Key Upcoming Clinical Trial Results (CYTK, $10.17)

Cytokinetics: Critical Phase IIB Data is Upcoming in 2013 for Omecamtiv Mecarbil and Tirasemtiv (CYTK, Buy. $6.30)